Head-To-Head Analysis: Argos Therapeutics (ARGS) versus Its Peers
Argos Therapeutics (NASDAQ: ARGS) is one of 48 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it contrast to its rivals? We will compare Argos Therapeutics to similar businesses based on the strength of its analyst recommendations, institutional ownership, profitability, valuation, earnings, risk and dividends.
This table compares Argos Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Argos Therapeutics Competitors||-13,604.51%||-112.81%||-28.65%|
Volatility and Risk
Argos Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Argos Therapeutics’ rivals have a beta of 1.09, indicating that their average share price is 9% more volatile than the S&P 500.
Valuation & Earnings
This table compares Argos Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Argos Therapeutics||$950,000.00||-$53.02 million||-0.15|
|Argos Therapeutics Competitors||$564.12 million||$96.17 million||40.34|
Argos Therapeutics’ rivals have higher revenue and earnings than Argos Therapeutics. Argos Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
18.4% of Argos Therapeutics shares are held by institutional investors. Comparatively, 43.2% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 28.2% of Argos Therapeutics shares are held by insiders. Comparatively, 15.5% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a summary of recent ratings and recommmendations for Argos Therapeutics and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Argos Therapeutics Competitors||134||799||1748||59||2.63|
Argos Therapeutics currently has a consensus price target of $4.13, suggesting a potential upside of 2,331.37%. As a group, “Biopharmaceuticals” companies have a potential upside of 13.35%. Given Argos Therapeutics’ higher possible upside, analysts plainly believe Argos Therapeutics is more favorable than its rivals.
Argos Therapeutics rivals beat Argos Therapeutics on 9 of the 12 factors compared.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.